Our expert team is here to guide you through every step of the process, from setting realistic goals to celebrating your success
The reality is more nuanced and formula-dependent
I think the results were expected, but they were even better than we thought they would be. Bilchick and colleagues conducted a retrospective, single-center study of 13,034 patients without AF at baseline who initiated GLP-1 use between January 2020 and May 2024 (mean age, 55 years
Tirzepatide (10mg-30mg), Dual-Action Incretin Co-Agonist Engineered Engagement of GIP and GLP-1 Receptors Introduction Engineered Engagement of GIP and GLP-1 Receptors Tirzepatide is a 39-residue synthetic peptide engineered to simultaneously activate two distinct incretin receptors, the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), within a single molecular scaffold
However, results vary, may be temporary, and cosmetic injection use raises important safety and regulatory concerns
